In this Review, Zelniker and Braunwald summarize the cardioprotective effects of empagliflozin and other sodium–glucose cotransporter 2 inhibitors and discuss the underlying mechanisms of these effects, including haemodynamic modulation, improved mitochondrial bioenergetics and activation of cytoprotective pathways that inhibit oxidative stress, inflammation and fibrosis.